Bouillot P, Pellissier J F, Devictor B, Graziani N, Bianco N, Grisoli F, Figarella-Branger D
Department of Pathology, Hôpital de la Timone, Marseille, France.
J Neurosurg. 1994 Nov;81(5):765-73. doi: 10.3171/jns.1994.81.5.0765.
Quantitative imaging of estrogen receptors (ER's), progesterone receptors (PR's), estrogen-regulated protein (pS2), and growth fraction (Ki67) immunocytochemical assays were performed in 52 meningiomas. The results were correlated with clinical (age, sex, hormonal status, and tumor volume and location) and morphological (histological types and grades) data. The authors observed a lack of ER's in all meningiomas but the presence of PR's in 53% of these meningiomas. The immunoreactivity was restricted to tumor cell nuclei. The PR immunocytochemical assay was correlated with tumor location, histological type, histological grade, and pS2 immunocytochemical assay, but not with Ki67 immunocytochemical assay; high PR content was observed in cisternae, transitional, meningothelial, and low-grade meningiomas. Only 11 meningiomas showed more than 1% Ki67 immunoreactive nuclei. These meningiomas were usually located in the convexity and were of high histological grade. Estrogen-regulated protein immunoreactivity was observed in 34 meningiomas but the number of immunoreactive nuclei was low. The pS2 immunocytochemical assay was not related to clinicopathological features but was preferentially observed in PR-negative meningiomas. The results of this study are compared with those previously reported, and the function and regulation of PR's in meningiomas is discussed. The results indicate that 1) regulation of PR's and pS2 proteins in meningiomas differs from regulation in estrogen-dependent tissues such as breast or endometrium; 2) interruption of hormonal therapy in women presenting with a meningioma is not absolutely necessary; 3) meningiomas have different biological properties according to their clinicopathological features; and 4) future studies of hormonal clinical trials should be performed on well-defined meningioma subgroups.
对52例脑膜瘤进行了雌激素受体(ER)、孕激素受体(PR)、雌激素调节蛋白(pS2)和增殖分数(Ki67)免疫细胞化学定量检测。结果与临床(年龄、性别、激素状态、肿瘤体积和位置)及形态学(组织学类型和分级)数据相关。作者观察到所有脑膜瘤均缺乏ER,但53%的脑膜瘤存在PR。免疫反应仅限于肿瘤细胞核。PR免疫细胞化学检测与肿瘤位置、组织学类型、组织学分级及pS2免疫细胞化学检测相关,但与Ki67免疫细胞化学检测无关;在脑池、过渡型、脑膜内皮型和低级别脑膜瘤中观察到高PR含量。仅11例脑膜瘤显示Ki67免疫反应性细胞核超过1%。这些脑膜瘤通常位于脑凸面,且组织学分级高。在34例脑膜瘤中观察到雌激素调节蛋白免疫反应性,但免疫反应性细胞核数量较少。pS2免疫细胞化学检测与临床病理特征无关,但在PR阴性脑膜瘤中更易观察到。将本研究结果与先前报道的结果进行了比较,并讨论了PR在脑膜瘤中的功能和调节。结果表明:1)脑膜瘤中PR和pS2蛋白的调节不同于乳腺或子宫内膜等雌激素依赖性组织中的调节;2)患有脑膜瘤的女性中断激素治疗并非绝对必要;3)脑膜瘤根据其临床病理特征具有不同的生物学特性;4)未来激素临床试验研究应针对明确界定的脑膜瘤亚组进行。